期刊
NUCLEAR MEDICINE COMMUNICATIONS
卷 42, 期 4, 页码 421-428出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MNM.0000000000001341
关键词
analog PET; CT; digital PET; CT; [F-18]FDG; liver lesion detectability
资金
- Philips Healthcare
Digital PET/CT offers improved detectability of liver lesions over analog PET/CT in patients with known or suspected liver metastases, detecting a significantly higher number of liver lesions and being able to detect additional lesions that the analog system missed.
Aim To assess if digital PET/CT improves liver lesion detectability compared to analog PET/CT in patients with known or suspected liver metastases. Materials and methods We prospectively included 83 cancer patients, with one or more of these conditions: history of liver metastases, clinical risk of having liver metastases or presence of suspected liver metastases on the first of the two PET/CTs. All patients were consecutively scanned on each PET/CT on the same day after a single [F-18]fluorodeoxyglucose dose injection. The order of acquisition was randomly assigned. Three nuclear medicine physicians assessed both PET/CTs by counting the foci of high uptake suspicious of liver metastases. Findings were correlated with appropriate reference standards; 19 patients were excluded from the analysis due to insufficient lesion nature confirmation. The final sample consisted of 64 patients (34 women, mean age 68 +/- 12 years). Results As per-patient analysis, the mean number of liver lesions detected by the digital PET/CT (3.84 +/- 4.25) was significantly higher than that detected by the analog PET/CT (2.91 +/- 3.31); P < 0.001. Fifty-five patients had a positive PET/CT study for liver lesions. In 26/55 patients (47%), the digital PET/CT detected more lesions; 7/26 patients (27%) had detectable lesions only by the digital system and had Conclusion Digital PET/CT offers improved detectability of liver lesions over the analog PET/CT in patients with known or suspected liver metastases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据